These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32059734)

  • 21. A Gene Scan Study of
    Liu J; Bu J
    Chin Med J (Engl); 2017 Nov; 130(22):2709-2712. PubMed ID: 29133760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
    Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
    Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
    Deng C; Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera TK; Khan N; Besirli CG
    Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1543-1550. PubMed ID: 35001204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial.
    Koenekoop RK; Sui R; Sallum J; van den Born LI; Ajlan R; Khan A; den Hollander AI; Cremers FP; Mendola JD; Bittner AK; Dagnelie G; Schuchard RA; Saperstein DA
    Lancet; 2014 Oct; 384(9953):1513-20. PubMed ID: 25030840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of Mutations in the 65-kDa Retinal Pigment Epithelium (RPE65) Gene-Mediated Inherited Retinal Dystrophies: A Systematic Literature Review.
    Sallum JMF; Kaur VP; Shaikh J; Banhazi J; Spera C; Aouadj C; Viriato D; Fischer MD
    Adv Ther; 2022 Mar; 39(3):1179-1198. PubMed ID: 35098484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Cross-Sectional and Longitudinal Study of Retinal Sensitivity in RPE65-Associated Leber Congenital Amaurosis.
    Kumaran N; Rubin GS; Kalitzeos A; Fujinami K; Bainbridge JWB; Weleber RG; Michaelides M
    Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3330-3339. PubMed ID: 30025081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RPE65 Mutations in Two Japanese Families with Leber Congenital Amaurosis.
    Katagiri S; Hayashi T; Kondo M; Tsukitome H; Yoshitake K; Akahori M; Ikeo K; Tsuneoka H; Iwata T
    Ophthalmic Genet; 2016 Jun; 37(2):161-9. PubMed ID: 25495949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy for RPE65-related retinal disease.
    Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
    Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel RPE65 mutations associated with Leber congenital amaurosis in Chinese patients.
    Xu F; Dong Q; Liu L; Li H; Liang X; Jiang R; Sui R; Dong F
    Mol Vis; 2012; 18():744-50. PubMed ID: 22509104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
    Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
    Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
    Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
    Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudo-fovea formation after gene therapy for RPE65-LCA.
    Cideciyan AV; Aguirre GK; Jacobson SG; Butt OH; Schwartz SB; Swider M; Roman AJ; Sadigh S; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):526-37. PubMed ID: 25537204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
    Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
    Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa.
    Walia S; Fishman GA; Jacobson SG; Aleman TS; Koenekoop RK; Traboulsi EI; Weleber RG; Pennesi ME; Heon E; Drack A; Lam BL; Allikmets R; Stone EM
    Ophthalmology; 2010 Jun; 117(6):1190-8. PubMed ID: 20079931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations.
    Jacobson SG; Cideciyan AV; Aleman TS; Sumaroka A; Windsor EA; Schwartz SB; Heon E; Stone EM
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4573-7. PubMed ID: 18539930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
    Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
    Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.
    Gardiner KL; Cideciyan AV; Swider M; Dufour VL; Sumaroka A; Komáromy AM; Hauswirth WW; Iwabe S; Jacobson SG; Beltran WA; Aguirre GD
    Mol Ther; 2020 Jan; 28(1):266-278. PubMed ID: 31604676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
    Pierce EA; Bennett J
    Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success.
    Jacobson SG; Aleman TS; Cideciyan AV; Sumaroka A; Schwartz SB; Windsor EA; Traboulsi EI; Heon E; Pittler SJ; Milam AH; Maguire AM; Palczewski K; Stone EM; Bennett J
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6177-82. PubMed ID: 15837919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational screening of LCA genes emphasizing RPE65 in South Indian cohort of patients.
    Verma A; Perumalsamy V; Shetty S; Kulm M; Sundaresan P
    PLoS One; 2013; 8(9):e73172. PubMed ID: 24066033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.